Pharma

Your Article Summary

See Latest Articles

Patients Begin Enrolling into Investigator-Sponsored Phase 2 Trial of Antigenics? Oncophage Cancer Vaccine in Newly Diagnosed Glioma
Antigenics, 09/22/09

LEXINGTON and San Francisco—August 2009 —announced that the Brain Tumor Research Center at the University of California, San Francisco, has begun enrolling patients into a Phase 2 clinical trial of Oncophage in combination with the standard of care – radiation therapy plus Temodar – for newly diagnosed glioma patients. The overall goals of the investigator–sponsored study are to evaluate median overall survival, progression–free survival and immunologic response to vaccine treatment.

Today in Drug Trials...keeping you current

Receive free subspecialty "5-minute updates" via email

Data Presented at San Antonio Breast Cancer Symposium Demonstrate Treatment with Denosumab is Superior to the Standard of Care
Amgen, 12/11/09

A phase I dose-escalation and bioavailability study of oral and intravenous formulations of erlotinib (Tarceva, OSI-774) in patients with advanced solid tumors of epithelial origin
Cancer Chemotherapy and Pharmacology, 12/11/09

Repligen Reports Phase 3 Clinical Trial Results of RG1068 in Pancreatic Imaging
Repligen, 12/10/09

 See all of Drug Trials

Today in Research & Development...keeping you current

Receive free subspecialty "5-minute updates" via email

New study results presented at 2009 san antonio breast cancer symposium show importance of protecting your bones
Amgen, 12/11/09

Phase III CONFIRM study shows FASLODEX (fulvestrant) Injection 500 mg may delay time of disease progression over 250-mg dose in postmenopausal women with hormone receptor-positive advanced breast cancer
AstraZeneca, 12/11/09

Salix Pharmaceuticals Reports Concurrence with FDA on Content and Format of the Pending Rifaximin NDA in the Treatment of Non-Constipation Irritable Bowel Syndrome
Salix Pharmaceuticals, 12/11/09

 See all of Research & Development